Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 6/20 | 0.43 |
| ▸ | PFKFB4 | Q16877 | 6/20 | 0.43 |
| ▸ | HTR6 | P50406 | 3/20 | 0.42 |
| ▸ | CMA1 | P23946 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3695828 | 0.95 | CMA1 (0.43) | PFKFB3PFKFB4HTR6CMA1NPSR1 | |
| SCHEMBL13508598 | 0.89 | CMA1 (0.43) | CMA1FFAR1 | |
| SCHEMBL3683718 | 0.86 | PPARD (0.51) | PFKFB3PFKFB4PLA2G4AFFAR1 | |
| SCHEMBL3756003 | 0.85 | PPARA (0.41) | PFKFB3PFKFB4HTR6CMA1 | |
| SCHEMBL3689003 | 0.85 | CMA1 (0.42) | CMA1FFAR1 | |
| SCHEMBL3687141 | 0.84 | PTGIR (0.44) | PFKFB3PFKFB4HTR6CMA1 | |
| SCHEMBL13508319 | 0.82 | CMA1 (0.48) | PFKFB3PFKFB4HTR6CMA1NPSR1 | |
| SCHEMBL3689304 | 0.81 | PFKFB3 (0.41) | PFKFB3PFKFB4HTR6CMA1FFAR1 | |
| SCHEMBL3683554 | 0.81 | PPARD (0.44) | PFKFB3PFKFB4HTR6CMA1 | |
| SCHEMBL3689321 | 0.81 | HTR6 (0.39) | PFKFB3PFKFB4HTR6CMA1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | PFKFB3 507/4885PFKFB4 469/4885HTR6 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.